SREBF1 and fatty liver disease: This modification enhances the AR-driven transcription of lipogenic genes such as SREBP-1 and FASN, thereby promoting de novo lipogenesis and exacerbating liver steatosis, underscoring the intricate crosstalk between mTOR signaling and transcriptional regulation in hepatic lipid metabolism [4].